Cimetidine Captopril

Medications whose excretion is primarily renal and for which there is evidence of age-related reduction in renal and total body clearance include (but are not limited to) amantadine, aminoglycosides, atenolol, captopril, cimetidine, digoxin, lithium, and vancomycin. Some hepatically metabolized medications can yield active, primarily renally excreted metabolites such as iV-acetylprocainamide, normeperidine, and morphine-6-glucuronide, which can accumulate with advancing age owing to reduced renal function. 

Noninterfering amiloride, acebutolol, acenocoumarol, acetaminophen, aspirin, allopuri-nol, ambroxol, amoxicillin, atenolol, bendroflumethiazide, benzbromarone, bezafibrate, biperiden, bisacodyl, bromazepam, butizide, captopril, cimetidine, ciprofloxacin, clobu-tinol, clonidine, cotinine, diazepam, diclofenac, digitoxin, digoxin, dihydrocodeine, dihy-droergotamine, diltiazem, doxepin, doxycycline, enalapril, erythromycin, fenoterol, furosemide, glibenclamide, heparin, h3qjoxanthine, ibuprofen, indomethacin, isosorbide... 

The most frequent offenders are cytostatic agents and anticoagulants, but hair loss can occur with a variety of common drugs, including hormones, anticonvulsants, amantadine, amiodarone, captopril, cholesterol-lowering drugs, cimetidine, colchicine, etretinate, isotretinoin, ketoconazole, heavy metals, lithium, penicillamine, valproic acid, and propranolol. 

The development of cimetidine and captopril illustrate the new approach. Dozens of other drugs could have served as equally valid examples. These drugs are already well established in the market. Many of the agents under investigation now will only come to market after the turn of the century. The differences of opinion belie an underlying, widely shared philosophy ... 

Cimetidine did not appear to alter the pharmacokinetics or pharmacological effects of captopril or enalapril, or the pharmacokinetics of fosinopril or quinapril in studies in healthy subjects. The manufacturers of cilazapril say that no clinically significant interaction occurred with H2-receptor antagonists (not specifically named) and the manufacturers of moexipril, " ramipril, and trandolapril say that no important pharmacokinetic interaction occurred with cimetidine. The manufacturers of spirapril briefly note in a review that cimetidine did not alter the plasma concentrations of spirapril or its active metabolite spiraprilat. None of these pairs of drugs appears to interact to a clinically relevant extent, and no special precautions appear to be necessary. 

Richer C, Bah M, Cadilhac M, Thuillez C, Giudicelli JF. Cimetidine does not alter free unchanged captopril pharmacokinetics and biological effects in healthy volunteer. JPharmacol 0986) 17, 338-42. 

---